Horizon Discovery Group PLC (LON:HZD)‘s stock had its “buy” rating restated by Numis Securities Ltd in a note issued to investors on Tuesday. They presently have a GBX 260 ($3.39) price objective on the stock. Numis Securities Ltd’s price objective suggests a potential upside of 57.58% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. Panmure Gordon reaffirmed a “buy” rating and issued a GBX 270 ($3.52) price objective on shares of Horizon Discovery Group PLC in a report on Thursday, September 1st. Beaufort Securities reissued a “speculative buy” rating on shares of Horizon Discovery Group PLC in a report on Wednesday, September 14th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Horizon Discovery Group PLC has an average rating of “Buy” and an average price target of GBX 217.25 ($2.84).

Analyst Recommendations for Horizon Discovery Group PLC (LON:HZD)

Horizon Discovery Group PLC (LON:HZD) opened at 153.40 on Tuesday. Horizon Discovery Group PLC has a 1-year low of GBX 125.00 and a 1-year high of GBX 188.06. The firm has a 50-day moving average price of GBX 160.39 and a 200 day moving average price of GBX 160.58. The firm’s market cap is GBX 144.33 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/numis-securities-ltd-reaffirms-buy-rating-for-horizon-discovery-group-plc-hzd.html

Horizon Discovery Group PLC Company Profile

Horizon Discovery (LSE: HZD) is a world-leading gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. Horizon’s proprietary gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.

Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.